FDA panel reviews 1st new Alzheimer’s drug in 2 decades
WASHINGTON — Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease. The panel of … Read More
![]()

